Clinical trials: Acute Respiratory Infections
Infections, Streptococcal
A Study to Compare the Immunogenicity of GSK Biologicals' 10Pn-PD-DiT 4-dose Presentation to the Licensed 1-dose Synflorix™ (10Pn-PD-DiT) Vaccine When Co-administered With DTPw-combination Vaccine in Healthy Infants
The primary aim of the study is to demonstrate that an investigational 4-dose presentation of the 10Pn-PD-DiT vaccine with preservative is non-inferior to the licensed presentation of Synflorix (preservative-free) in terms of…
- Trial name
- NCT02447432
- Testing
- Pneumococcal vaccine GSK1024850A (10Pn-PD-DiT) vaccine (4-dose presentation), Pneumococcal vaccine GSK1024850A (10Pn-PD-DiT) vaccine (1-dose presentation), DTPw-HBV/Hib
- Where
- Bangladesh
- Volunteers
- 320 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Severe Acute Respiratory Syndrome
Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease
OSCAR (Otilimab in Severe COVID-19 Related Disease) is a multi-center, double-blind, randomized, placebo-controlled trial to assess the efficacy and safety of otilimab for the treatment of severe pulmonary COVID-19 related…
- Trial name
- OSCAR (NCT04376684)
- Testing
- Otilimab, Standard of care
- Where
- 120 sites in United States, Argentina and 17 more
- Volunteers
- 1,156 people
- Sponsor
- GlaxoSmithKline
Cough
Comparison Between Oxomemazine, Guaifenesin and Potassium Iodate Versus Guaifenesin Monotherapy in Acute Cough Treatment
The purpose of this study is evaluate if efficacy of a combination dose of oxomemazine, guaifenesin and potassium iodate is superior than guaifenesin monotherapy in acute cough treatment.
- Trial name
- NCT01257243
- Testing
- Syrup of oxomemazine, guaifenesin and potassium iodate, Syrup of guaifenesin
- Where
- Brazil
- Volunteers
- 260 people
- Sponsor
- EMS
Pulmonary Disease, Chronic Obstructive
Tiotropium (18mcg) in Chronic Obstructive Pulmonary Disease (COPD) Patients With a Respiratory Infection
The aim of the study is to investigate whether the early introduction of maintenance bronchodilator therapy during an acute symptomatic episode of the disease shows benefits on the recovery of symptoms.
- Trial name
- NCT01483625
- Testing
- tiotropium
- Where
- 27 sites in United States
- Volunteers
- 140 people
- Sponsor
- Boehringer Ingelheim
COVID-19
A Study to Learn About Bivalent COVID-19 RNA Vaccine Candidate(s) in Healthy Infants and Children
The purpose of this clinical trial is to learn about the safety and immune responses of the study vaccine (called a bivalent BNT162b2 Omicron containing vaccine) in healthy infants and children.
- Trial name
- NCT05630352
- Testing
- Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose, Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 6 microgram dose, Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose
- Volunteers
- healthy volunteers welcome
- Sponsor
- BioNTech SE
Maxillary Sinusitis
Trial to Evaluate Time to Symptom Relief and Elimination of Infecting Bacteria in Treating Sinusitis With Avelox
This study evaluated the time to bacteriological eradication of common pathogens during moxifloxacin therapy for acute bacterial maxillary sinusitis.
- Trial name
- SPEED (NCT00668304)
- Testing
- Avelox (Moxifloxacin, BAY12-8039)
- Where
- 35 sites in United States, Argentina
- Volunteers
- 192 people
- Sponsor
- Bayer
Acute Respiratory Distress Syndrome
Poractant Alfa (Curosurf®)) -- Effect in Adult Patients Diagnosed With 2019 Novel Coronavirus (SARS-COV-19; (Covid-19)) Acute Respiratory Distress Syndrome (ARDS)
The purpose of this study was to evaluate the efficacy and safety of poractant alfa (Curosurf®), administered by endotracheal (ET) instillation in hospitalized adult patients diagnosed with SARS-COV-19 acute respiratory distress…
- Trial name
- NCT04502433
- Testing
- CUROSURF® (poractant alfa)
- Where
- 6 sites in United States, Italy and 1 more
- Volunteers
- 22 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Covid19
Expanded Access to T89 for Treatment Use in Intermediate-size Patients Population With COVID-19
This expanded access use program will provide a botanical drug of T89 for treatment use in an intermediate-size population infected with SARS-CoV-2 who have severe COVID-19, or who are judged by a healthcare provider to be at…
- Trial name
- NCT04646031
- Testing
- T89 capsule
- Where
- United States
- Sponsor
- Tasly Pharmaceuticals, Inc.
ARDS, Human, Covid-19
Use of Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Caused by COVID-19
This is a pilot phase, open label, non-randomized study for the treatment of ARDS in patients infected with COVID-19. Subjects will be enrolled and treated with one dose of mesenchymal stem cells and follow-up will occur 90 days…
- Trial name
- NCT04456361
- Testing
- Mesenchymal Stem Cells derived from Wharton Jelly of Umbilical cords
- Where
- Mexico
- Volunteers
- 9 people
- Sponsor
- Instituto de Medicina Regenerativa
COVID-19
The KIN-FAST Trial (KIN001 For Accelerated Symptoms Termination) in Non Hospitalized Patients Infected With SARS-CoV-2
Clinical trial on safety and efficacy of KIN001 in non-hospitalized patients with COVID-19.
- Trial name
- KIN-FAST (NCT05659459)
- Testing
- KIN001
- Where
- 8 sites in Germany, Switzerland
- Volunteers
- 17 people
- Sponsor
- Kinarus AG
Sars-CoV-2 Infection
Safety, Tolerability and Immunogenicity of Alveavax-v1.2, a BA.2/Omicron-optimized, DNA Vaccine for COVID-19 Prevention
The investigated product is a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Booster Vaccine candidate optimized for the Omicron/BA.2 variant.
- Trial name
- NCT05844202
- Testing
- Alveavax-v1.2, Janssen Ad26.COV2.S
- Where
- 8 sites in South Africa
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Alvea Holdings, LLC
Cough
Efficacy and Safety of Rengalin in the Treatment of ARVI Cough in Children
The goal of this clinical trial is to evaluate the efficacy and safety of liquid dosage form of Rengalin in the treatment of cough in acute viral upper respiratory tract infections infections in children in during the epidemic…
- Trial name
- NCT07171099
- Testing
- Rengalin
- Where
- 30 sites in Russia
- Volunteers
- 264 people
- Sponsor
- Materia Medica Holding
Influenza, Acute Respiratory Viral Infections
Safety and Pharmacokinetics of Ingavirin Forte, Capsules, 90 mg + 20 mg (Valenta Pharm JSC, Russia) Compared With Ingavirin, Capsules, 90 mg, Under Fasting and Fed Conditions.
This study aims to evaluate the safety and pharmacokinetic profile of the active ingredients Ingavirin forte, capsules, 90 mg + 20 mg (Valenta Pharm JSC, Russia) relative to single-entity Drug Ingavirin, capsules, 90 mg following…
- Trial name
- NCT07645534
- Testing
- Ingavirin forte, capsules, 90 mg + 20 mg, Ingavirin, capsules, 90 mg
- Where
- Russia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Valenta Pharm JSC
Bronchitis, Chronic
AVANTI - Avelox® in Acute Exacerbations of chroNic bronchiTIs
The objective of this global non-interventional study is to evaluate the impact of Acute Exacerbation of Chronic Bronchitis(AECB) on the patient and the community as well as the safety and effect of a treatment with Moxifloxacin…
- Trial name
- NCT00846911
- Testing
- Moxifloxacin (Avelox, BAY12-8039)
- Where
- 8 sites in Albania, Bosnia and Herzegovina and 6 more
- Volunteers
- 2,672 people
- Sponsor
- Bayer
SARS-CoV-2 Acute Respiratory Disease
Study of the Evolution of Olfactory Disorders in Patients With Persistent Loss of Smell Following COVID-19
The COVID-19 pandemic is a novel medical challenge, particularly because of the systemic nature of this disease. Indeed, COVID-19 affects several organs and systems at once.
- Trial name
- ETOC (NCT05133596)
- Testing
- Clinical examination, Blood collection, Olfactory evoked potentials
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Institut Pasteur
Biological Availability, Healthy Participants
Relative Bioavailability Study of Nirmatrelvir/Ritonavir 4 Different Fixed Dose Combination Tablets Relative to the Commercial Tablets in Healthy Participants
The purpose of this study is to estimate the relative bioavailability of nirmatrelvir/ritonavir of 4 different FDC tablet formulations relative to the commercial tablet formulation under fasted conditions in healthy adult…
- Trial name
- NCT05525910
- Testing
- Nirmatrelvir/ ritonavir, Nirmatrelvir/ritonavir
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Pfizer
Hypertension, Hypoxia
The VISION-Acute Study
AIM: We propose an innovative approach using Lifelight® smart technology that will enable the continued provision of high level patient care at the same time as reducing pressure on nursing and equipment resources.
- Conditions
- Hypertension, Hypoxia, Hypotension
- Trial name
- NCT04589923
- Testing
- Lifelight® Data Collect Blood Pressure Group, Lifelight® Data Collect Oxygen Saturation Group
- Where
- United Kingdom
- Volunteers
- 127 people
- Sponsor
- Xim Limited
Respiratory Tract Infections
ProbioKid as Prevention Among Kids With Frequent URTI
This study was designed to evaluate the preventive efficacy of a 6-week prophylactic administration of Probiokid® on the incidence of respiratory infections and related complications in frequently sick children.
- Trial name
- NCT04525040
- Testing
- ProbioKid®, Pragmatic comparator
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Lallemand Health Solutions
Bronchiectasis, Lower Respiratory Infection
Safety, Efficacy and PK/PD of POL7080 in Patients With Exacerbation of Non-cystic Fibrosis Bronchiectasis.
To test whether POL7080 is effective in patients with exacerbation of non-cystic fibrosis bronchiectasis caused by Pseudomonas aeruginosa infection.
- Trial name
- NCT02096315
- Testing
- POL7080
- Where
- 4 sites in Spain, United Kingdom
- Volunteers
- 20 people
- Sponsor
- Polyphor Ltd.
Chronic Bronchitis
Moxifloxacin Versus Amoxicillin Clavulanic Acid in Treatment of Acute Exacerbation of Chronic Bronchitis
A study to assess the safety and efficacy of moxifloxacin compared to that of amoxicillin-clavulanic acid for the treatment of subjects with acute exacerbation of chronic bronchitis.
- Trial name
- NCT00656747
- Testing
- Avelox (Moxifloxacin, BAY12-8039), Amoxicillin clavulanic acid
- Where
- 220 sites in Andorra, Argentina and 29 more
- Volunteers
- 1,372 people
- Sponsor
- Bayer